Scientists in the U.K. have found that a new drug being tested for cancer therapy may also be able to reduce damage in patients with spinal cord injuries.
Biologics
Spiderwort, a startup developing cellulose-based tissue scaffolding to treat acute spinal cord injuries, has secured $13.2 million through a series A financing round, the company said July 12.
Regenerative medicine in orthopedics has developed in the first half of 2022, and many surgeons have a positive outlook toward it.
AlloSource added the AlloFuse microfibers demineralized bone allograft to its product line.
Istos Biologics launched the Influx Fibrant line of 100 percent cortical allograft products.
Advertisement
Aziyo Biologics co-founder Randal Mills, PhD, was named interim president and CEO.
Theradaptive's OsteoAdapt SP implant received its third FDA breakthrough designation.
A Cincinnati pain management physician led the first prospective controlled trial in the world on treating chronic back pain with stem cells, with about 70 percent of participants seeing positive results.
Royal Biologics received FDA approval for its MAXX-BMC bone marrow aspirate concentration system.
Although further research is needed to determine the safety and efficacy of regenerative procedures in the spine, the potential of many of these therapies — such as stem cells, platelet-rich plasma and bone marrow aspirate — is considerable.